Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 855 clinical trials
Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent

SORT OUT XI Comparison of Combo stent and BioMatrix Alpha stent in the treatment of unselected patients with ischemic heart disease.

heart disease
sirolimus
  • 4 views
  • 27 Apr, 2021
  • 2 locations
Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease (BioVasc)

To test whether immediate complete revascularization is non-inferior to staged (but within six weeks after index procedure) complete revascularization in Patients presenting with ACS, including Non-ST-elevation ACS (NSTEACS) and ST-elevation myocardial infarction (STEMI), with multivessel disease accepted for PCI

unstable angina
angina pectoris
chest pain
sirolimus
acute coronary syndrome
  • 0 views
  • 12 Feb, 2022
  • 1 location
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome (TACSI)

The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary syndrome.

unstable angina
angina pectoris
stemi
acute coronary syndrome
antiplatelet therapy
  • 6 views
  • 14 Feb, 2022
  • 18 locations
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE in ACS patients undergoing PCI compared to clopidogrel. This benefit came without any increase in major bleedings compared to clopidogrel …

  • 0 views
  • 30 Jan, 2021
  • 1 location
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study (STOPDAPT-3)

The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coroanry intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk …

everolimus
clopidogrel
percutaneous coronary intervention
acute coronary syndrome
aspirin
  • 0 views
  • 23 Apr, 2022
  • 1 location
Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

sirolimus
ticagrelor
thrombosis
dapt
antiplatelet therapy
  • 10 views
  • 22 Jan, 2021
  • 1 location
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial (NEOMINDSET)

Phase-3, randomized, multicenter, parallel-group study with blind evaluation of endpoints and intention-to-treat analysis. The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy …

acute coronary syndrome
percutaneous coronary intervention
antiplatelet therapy
ticagrelor
  • 22 views
  • 04 Oct, 2022
  • 29 locations
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

arterial disease
acute coronary syndrome
diabetes
stroke
percutaneous coronary intervention
  • 1233 views
  • 27 Oct, 2022
  • 1647 locations
Does the Advice to Eat a Mediterranean Diet With Low Carbohydrate Intake, Compared With a Low-fat Diet, Reduce Diabetes and Cardiovascular Disease?

This is a multi-centre, open, randomised study in patients treated for ischemic heart disease in Linkping, Norrkping and Jnkping hospitals. One thousand two hundred patients who are treated at

rehabilitation therapy
cardiovascular disease
diabetes
heart disease
low-fat diet
  • 78 views
  • 24 Feb, 2022
  • 1 location
A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients (TIGER)

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

acute coronary syndrome
percutaneous coronary intervention
aspirin
ticagrelor
  • 4 views
  • 23 Apr, 2022
  • 4 locations